scholarly journals Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review

2020 ◽  
Vol 21 (17) ◽  
pp. 6187
Author(s):  
Paolo Cameli ◽  
Elena Bargagli ◽  
Laura Bergantini ◽  
Miriana d’Alessandro ◽  
Maria Pieroni ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Exhaled Nitric Oxide ◽  
Inhalation Therapy ◽  
Asthmatic Patients ◽  
Promising Tool ◽  
Multiple Flows ◽  
Published Evidence

Fractional exhaled nitric oxide (FeNO) is a well-known and widely accepted biomarker of airways inflammation that can be useful in the therapeutic management, and adherence to inhalation therapy control, in asthmatic patients. However, the multiple-flows assessment of FeNO can provide a reliable measurement of bronchial and alveolar production of NO, supporting its potential value as biomarker also in peripheral lung diseases, such as interstitial lung diseases (ILD). In this review, we first discuss the role of NO in the pathobiology of lung fibrosis and the technique currently approved for the measurement of maximum bronchial flux of NO (J’awNO) and alveolar concentration of NO (CaNO). We systematically report the published evidence regarding extended FeNO analysis in the management of patients with different ILDs, focusing on its potential role in differential diagnosis, prognostic evaluation and severity assessment of disease. The few available data concerning extended FeNO analysis, and the most common comorbidities of ILD, are explored too. In conclusion, multiple-flows FeNO analysis, and CaNO in particular, appears to be a promising tool to be implemented in the diagnostic and prognostic pathways of patients affected with ILDs.

scholarly journals Exhaled nitric oxide in interstitial lung diseases

2014 ◽  
Vol 197 ◽  
pp. 46-52 ◽  
Author(s):  
P. Cameli ◽  
E. Bargagli ◽  
R.M. Refini ◽  
M.G. Pieroni ◽  
D. Bennett ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Exhaled Nitric Oxide

Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases

2015 ◽  
Author(s):  
Paolo Cameli ◽  
Elena Bargagli ◽  
David Bennett ◽  
Rosa Metella Refini ◽  
Paola Rottoli
Keyword(s):  
Nitric Oxide ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Exhaled Nitric Oxide

Role of exhaled nitric oxide in predicting steroid response in chronic obstructive pulmonary disease

2010 ◽  
Vol 151 (51) ◽  
pp. 2083-2088 ◽  
Author(s):  
Balázs Antus
Keyword(s):  
Nitric Oxide ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Exhaled Nitric Oxide ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Steroid Response

A kilégzett levegőben mérhető nitrogén-monoxid a legszélesebb körben vizsgált légúti biomarker. A stabil állapotú krónikus obstruktív tüdőbetegségben a kilégzett nitrogén-monoxid-szint hasonló vagy csak kismértékben emelkedett az egészségesekhez képest. Mivel a nitrogén-monoxid-szint szoros összefüggést mutat a légúti eosinophilia mértékével, és mivel az eosinophil típusú légúti gyulladás szteroidokra érzékenyebb, az emelkedett nitrogén-monoxid-szinttel rendelkező betegek jobb válaszkészséget mutatnak az inhalációs vagy szisztémás kortikoszteroidkezelésre. A krónikus obstruktív tüdőbetegség akut exacerbatiója során a kilégzett nitrogén-monoxid szintje megemelkedik, majd ennek kezelése után csökken. Mivel a nitrogén-monoxid-szint és a kezelés során elért légzésfunkciós javulás szoros korrelációt mutat egymással, a nitrogén-monoxid-méréssel a terápiás válasz megjósolható. Összefoglalva: a nitrogén-monoxid-méréssel a krónikus obstruktív tüdőbetegségben szenvedő betegek olyan alcsoportját lehet elkülöníteni, amelynek szteroidérzékenysége nagyobb. Orv. Hetil., 2010, 151, 2083–2088.

scholarly journals Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale

2020 ◽  
Vol 201 (2) ◽  
pp. 260-261
Author(s):  
Arnaud Bourdin ◽  
Carey M. Suehs ◽  
Thomas V. Colby ◽  
Isabelle Vachier ◽  
Nicolas Molinari ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Interstitial Lung Diseases

The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients

2014 ◽  
Vol 35 (3) ◽  
pp. 241-249 ◽  
Author(s):  
M. Asghar Pasha ◽  
David Jourd'heuil ◽  
Francis Jourd'heuil ◽  
Lori Mahon ◽  
Francisco Romero ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Airway Inflammation ◽  
Exhaled Nitric Oxide ◽  
Small Airway ◽  
Asthmatic Patients ◽  
Severe Asthmatic

The Utility of Serum IL-1β and CRP Together with Fractional Exhaled Nitric Oxide in the Diagnosis of Asthma in Adults

2021 ◽  
Vol 19 (8) ◽  
pp. 119-124
Author(s):  
Hayder Abdul-Amir Makki Al-Hindy ◽  
Ali Jihad Hemid Al-Athari ◽  
Mazin J. Mousa ◽  
Safa Jihad Hameed ◽  
Suhad Hafidh Obeed
Keyword(s):  
Nitric Oxide ◽  
Sensitivity And Specificity ◽  
Bronchial Asthma ◽  
High Sensitivity ◽  
Exhaled Nitric Oxide ◽  
Fractional Exhaled Nitric Oxide ◽  
Asthmatic Patients ◽  
Significant Difference ◽  
Asthma Patients ◽  
Hs Crp

Background: Bronchial asthma (BrA), recognized lately as an umbrella, covers various subtypes rather than only one disease. Asthma is a chronic inflammation of the airways, in which cytokines could play a crucial role in its pathogenesis. Hence, labors to progress noninvasive markers for asthma had centered through this era. Presently, the fractional exhaled nitric oxide (FeNO), serum C-reactive protein (CRP), and interleukin levels are emerging analytical biomarkers in this field. FeNO is a noninvasive and practical tool even in mild asthma. This study aimed to evaluate the utility of serum IL-1β and CRP together with fractional exhaled nitric oxide in the diagnosis of adult bronchial asthma. Method: The study was a case control, including 150-patients and 100-healthy controls. FeNO tests, measurements of plasma levels IL-1β and HS-CRP had undertaken for all the participants. The statistical data had examined by SPSS (V/27) for Windows. Descriptive data of the variables had compatibly used. A significance lower than or identical to 0.05 had intended. ROC curve examination of FeNO tests, IL-1β, and HS-CRP, to predict asthma from healthy control had applied. Results: there was a significant difference in the FeNo test, HS-CRP levels, and BMI, while no significant difference in all other variables between the groups. The FeNo results correlate positively, though not significantly, with the levels of IL-1β in asthmatic patients (> 0.05). There was a nonsignificant negative correlation between the FeNo results with the level of HSCRP. The accuracy, sensitivity, and specificity of the IL-1β to distinguish asthma were 68.6% and 58% at 95% CI [0.41-0.745], respectively, which was not significant (p>0.05). However, ROC analysis of HS-CRP revealed predictability for asthma patients (p-0.000), with higher accuracy, sensitivity, and specificity: 89.9%, and 68.1% at 95% CI [0.820-0.979], respectively. The FeNo tests revealed highly significant (0.000), high sensitivity, and specific (91% for both) with high 95% CI [0.938-1.000] predictability for asthma. Conclusion: The utility of circulating HS-CRP is more valuable than IL-1β when combined with fractional exhaled nitric oxide in the diagnosis of asthma. Novel biomarkers could improve the precision of this field.

Sign in / Sign up

Export Citation Format

Share Document